Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

PNAS 103 (48): 18238-18242

Copyright © 2006 by the National Academy of Sciences.

Human cancers express a mutator phenotype

Jason H. Bielas, Keith R. Loeb*, Brian P. Rubin, Lawrence D. True, and Lawrence A. Loeb{dagger}

Department of Pathology, University of Washington, Seattle, WA 98195


Figure 1
View larger version (23K):
[in this window]
[in a new window]

 
Fig. 1.. The RMC applied to human tissue. Genomic DNA is isolated from intact tissue and digested with restriction enzymes that do not cut the mutational target sequence, a 4-bp TaqI restriction site (TCGA) in intron VI of p53; blue lines represent the wild-type target sequence, and red lines represent mutant target sequence. A complementary probe (gray lines) that contains dUMP in place of dTMP and a biotinylated nucleotide at the 5' terminus is hybridized to the mutational target. The hybridized target is isolated by complexing to magnetic beads, digested with TaqI (cleaving the TCGA target site in the wild-type sequence and failing to cleave if a nucleotide substitution is present at that site), and denatured. Rehybridization and TaqI digestion are carried out four times. The probe is then disabled for further hybridization by digestion with uracil-DNA glycosylase, and the mutational target is diluted in 96-well plates so that 1 in {approx}10 wells contains a PCR-amplifiable product (red wells) as measured with SYBR green by using real-time QPCR. The mutation frequency is quantified by QPCR amplification and is calculated as the number of wells containing a mutant sequence divided by the product of the total number of target molecules screened and the restriction site length (bp). The mutant sequence of the amplified product in all positive wells is verified by DNA sequencing; C4 and G8 represent the mutant sequences found in wells C4 and G8, respectively, of the 96-well plate shown. In some cases, preliminary verification was carried out by redigestion with TaqI.

 

Figure 2
View larger version (73K):
[in this window]
[in a new window]

 
Fig. 2.. Matched normal and neoplastic tissues analyzed in the RMC assay. Hematoxylin/eosin-stained sections of the paired normal (Left) and tumor (Right) tissues listed in Table 1 are shown. The tissues are normal squamous vaginal epithelium and high-grade papillary serous ovarian carcinoma with psammoma bodies; normal renal cortex and dedifferentiated sclerosing perirenal liposarcoma; normal colonic mucosa and invasive colonic adenocarcinoma; renal cortex with lymphocytic inflammation and malignant renal epithelioid angiomyolipoma; and normal skeletal muscle and high-grade malignant fibrous histiocytoma pleomorphic sarcoma. Immunohistochemical analysis of MLH1 and MSH2 proteins involved in DNA mismatch repair showed the colonic adenocarcinoma to lack MLH1 expression and to have normal expression of MSH2. These results suggest that the tumor is defective in mismatch repair. The mutation frequencies measured in the RMC assay are indicated below each section.

 

Figure 3
View larger version (14K):
[in this window]
[in a new window]

 
Fig. 3.. Tumor mutation spectrum. DNA sequencing of all mutants recovered from tumors showed that C·G to T·A transitions were the most common mutation, and the sequencing permitted distinction between independent random mutational events (gray bars, mutation observed only once) and expansion of mutant clones (white bars, same mutation recovered more than once in the same tumor). Identical mutations observed more than once (expanded mutations) are recorded as one single event; the number of these minority events is indicated by the relatively short length of the white bar extending past the gray bar.

 


To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882